QuidelOrtho (NASDAQ:QDEL) Issues FY 2026 Earnings Guidance

QuidelOrtho (NASDAQ:QDEL) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.650-0.900 for the period, compared to the consensus estimate of 1.850. The company issued revenue guidance of $2.5 billion-$2.6 billion, compared to the consensus revenue estimate of $2.7 billion.

QuidelOrtho Stock Performance

Shares of QuidelOrtho stock traded down $3.73 on Friday, reaching $12.60. 2,775,868 shares of the stock were exchanged, compared to its average volume of 1,763,377. The firm has a market capitalization of $858.85 million, a price-to-earnings ratio of -0.71 and a beta of 0.68. The business has a 50 day moving average price of $15.77 and a two-hundred day moving average price of $17.59. QuidelOrtho has a twelve month low of $9.92 and a twelve month high of $35.58. The company has a quick ratio of 0.80, a current ratio of 1.43 and a debt-to-equity ratio of 1.33.

QuidelOrtho (NASDAQ:QDEL) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.18. QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The firm had revenue of $630.90 million during the quarter, compared to analyst estimates of $618.72 million. During the same quarter in the previous year, the business earned $0.12 EPS. QuidelOrtho’s revenue for the quarter was up 2.8% compared to the same quarter last year. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. Analysts anticipate that QuidelOrtho will post 1.87 earnings per share for the current fiscal year.

Analysts Set New Price Targets

QDEL has been the subject of a number of research reports. Citigroup lifted their price objective on shares of QuidelOrtho from $13.00 to $18.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of QuidelOrtho in a research report on Friday, July 17th. Zacks Research upgraded shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a research note on Monday, June 15th. JPMorgan Chase & Co. upped their price objective on QuidelOrtho from $11.00 to $12.00 and gave the stock an “underweight” rating in a research report on Wednesday, July 1st. Finally, UBS Group reiterated a “neutral” rating and issued a $12.00 price objective on shares of QuidelOrtho in a research note on Thursday, May 7th. Four research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus target price of $13.62.

Key Stories Impacting QuidelOrtho

Here are the key news stories impacting QuidelOrtho this week:

• Positive Sentiment: QuidelOrtho reported second-quarter adjusted earnings of $0.13 per share, compared with analysts’ expected loss of approximately $0.04–$0.05 per share. Revenue of $630.9 million also exceeded the $618.7 million consensus estimate. QuidelOrtho Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Quarterly revenue grew about 3% year over year, driven primarily by the Labs and Point-of-Care businesses. Excluding China, revenue increased 6% both on a reported and constant-currency basis, suggesting stronger underlying demand outside that market. QuidelOrtho Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Management discussed the second-quarter performance and updated outlook during the earnings call. Investors will look for additional detail on demand trends, China, cost controls and the path to sustained profitability. QuidelOrtho Q2 2026 Earnings Call Transcript
• Negative Sentiment: QuidelOrtho cut its FY 2026 EPS guidance to $0.65–$0.90, far below the approximately $1.85 analyst consensus. It also forecast revenue of $2.5–$2.6 billion versus expectations of roughly $2.7 billion, creating a major negative earnings revision. QuidelOrtho Q2 Sales and Stock Reaction
• Negative Sentiment: Despite the quarterly beat, the company remains loss-making on a GAAP net-margin basis, with a reported negative net margin of 45.57%. The combination of modest overall growth and sharply lower guidance likely outweighed the better-than-expected quarter. QuidelOrtho Q2 Earnings Snapshot

Institutional Trading of QuidelOrtho

Hedge funds have recently modified their holdings of the business. Corient Private Wealth LLC bought a new stake in shares of QuidelOrtho in the 4th quarter valued at $280,000. Schonfeld Strategic Advisors LLC raised its stake in QuidelOrtho by 47.1% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 15,520 shares of the company’s stock worth $443,000 after buying an additional 4,969 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in QuidelOrtho by 97.7% in the fourth quarter. Russell Investments Group Ltd. now owns 13,577 shares of the company’s stock valued at $392,000 after buying an additional 6,708 shares during the period. CIBC Bancorp USA Inc. acquired a new position in QuidelOrtho in the third quarter valued at $213,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in QuidelOrtho by 13.5% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,038 shares of the company’s stock valued at $561,000 after acquiring an additional 2,265 shares during the last quarter. 99.00% of the stock is owned by institutional investors and hedge funds.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.